Want to see SE:IBT.B full AI Analyst Report?
Infant Bacterial Therapeutics AB (IBT.B) AI Stock Analysis
Top Page
Infant Bacterial Therapeutics AB
(Nasdaq OMX AB:IBT.B)
The score is primarily held down by very weak fundamentals (zero revenue, ongoing losses, and persistent cash burn) and a hard-to-justify valuation signal due to negative earnings. A debt-free balance sheet and mostly neutral technical momentum provide some stabilization but are not strong enough to offset the financial profile.
Infant Bacterial Therapeutics AB (IBT.B) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 885.07M
- Dividend Yield
- ―
- Average Volume (3M)
- 8,717
- Price to Earnings (P/E)
- -10.8
- Beta (1Y)
- -0.49
- Revenue Growth
- ―
- EPS Growth
- 19.94%
- Country
- Sweden
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Infant Bacterial Therapeutics AB Business Overview & Revenue Model
Company Description
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is...
How the Company Makes Money
Infant Bacterial Therapeutics AB is a clinical-stage biotechnology company and, based on publicly available information, it has not been characterized as generating material recurring revenue from product sales. Its primary economic model is to inves...
Infant Bacterial Therapeutics AB Financial Statement Overview
Summary
Financial performance is very weak: TTM revenue is 0 with sizable losses (EBIT about -85M; net loss about -82M) and continued negative operating/free cash flow (both about -64M). The main offset is a debt-free balance sheet, but equity has declined sharply over time, reflecting ongoing dilution/erosion until commercialization or partnering revenue materializes.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 4,000 | 77.00K | 12.00K | 0 |
| Gross Profit | 0 | 0 | 4,000 | 77.00K | 12.00K | 0 |
| EBITDA | -82.02M | -68.18M | -136.09M | -122.25M | -64.34M | -43.76M |
| Net Income | -81.92M | -65.17M | -136.91M | -123.07M | -65.45M | -44.99M |
Balance Sheet | ||||||
| Total Assets | 120.22M | 161.75M | 239.57M | 351.33M | 349.62M | 408.48M |
| Cash, Cash Equivalents and Short-Term Investments | 108.60M | 144.01M | 223.39M | 329.06M | 335.84M | 386.75M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 67.20M | 56.42M | 69.30M | 46.18M | 17.91M | 13.22M |
| Stockholders Equity | 53.02M | 105.33M | 170.26M | 305.15M | 331.71M | 395.25M |
Cash Flow | ||||||
| Free Cash Flow | -64.06M | -72.34M | -113.13M | -101.22M | -85.80M | -55.62M |
| Operating Cash Flow | -64.06M | -72.34M | -113.13M | -101.22M | -85.80M | -55.62M |
| Investing Cash Flow | 0 | 0 | 0 | -4.15M | -1,000 | 0 |
| Financing Cash Flow | 0 | 0 | 2.01M | 96.52M | 1.88M | 91.00K |
Infant Bacterial Therapeutics AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IBT.B, the sentiment is Negative. The current price of 65.70 is below the 20-day moving average (MA) of 74.70, below the 50-day MA of 69.58, and above the 200-day MA of 59.98, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 38.91 is Neutral, neither overbought nor oversold. The STOCH value of 17.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IBT.B.
Infant Bacterial Therapeutics AB Peers Comparison
Overall Rating
SE:HNSA55Neutral
SE:XBRANE54Neutral
SE:BINV43Neutral- SE:IBT.B42Neutral
SE:IVACC41Neutral
SE:EXPRS237Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:HNSA | 55Neutral | SEK 4.00B | -5.00 | ― | ― | -3.57% | 8.84% |
| SE:XBRANE | 54Neutral | SEK 291.57M | -5.90 | -13.41% | ― | -38.80% | -120.18% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:BINV | 43Neutral | SEK 357.32M | -0.73 | -128.54% | ― | -83.67% | -50.29% |
| SE:IBT.B | 42Neutral | SEK 885.07M | -10.79 | -89.70% | ― | ― | 19.94% |
| SE:IVACC | 41Neutral | SEK 263.11M | -2.92 | -34.25% | ― | -0.71% | 54.16% |
| SE:EXPRS2 | 37Underperform | SEK 36.86M | -0.14 | -104.71% | ― | -2.29% | 55.71% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:IBT.B | Infant Bacterial Therapeutics | 65.70 | 5.80 | 9.68% | |
| SE:HNSA | Hansa Biopharma | 39.34 | 8.34 | 26.90% | |
| SE:BINV | BioInvent International AB | 5.43 | -28.47 | -83.98% | |
| SE:XBRANE | Xbrane Biopharma AB | 14.15 | 3.35 | 31.02% | |
| SE:IVACC | Intervacc AB | 0.77 | -0.20 | -20.33% | |
| SE:EXPRS2 | ExpreS2ion Biotech Holding AB | 0.93 | -5.16 | -84.67% |
Infant Bacterial Therapeutics AB Corporate Events
IBT Secures FDA Pre-BLA Meeting for Breakthrough Neonatal Therapy
Infant Bacterial Therapeutics AB, a Stockholm-based pharmaceutical company listed on Nasdaq Stockholm, specializes in therapies for premature infants, led by its live biotherapeutic candidate IBP-9414 derived from bacteria in human breast milk. The f...
Infant Bacterial Therapeutics Sets Nomination Committee Ahead of 2027 AGM
Infant Bacterial Therapeutics AB has appointed its Nomination Committee for the 2027 Annual General Meeting, in line with its established governance framework and based on the ownership structure as of June 30, 2026. The committee includes representa...
Infant Bacterial Therapeutics Advances IBP-9414 Toward Market Despite Wider Losses
Infant Bacterial Therapeutics AB reported no net sales for the first half of 2026 and a widened operating loss, reflecting its pre-commercial stage as it advances its lead neonatal drug candidate IBP-9414 toward market approval. Despite the financial...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026